BNP PARIBAS ARBITRAGE/CALL/MODERNA/105/0.1/21.06.24 Stock

Warrant

G61NB

NLBNPFR1YB50

Market Closed - Euronext Paris 12:30:01 2024-05-31 EDT
3.53 EUR -12.41% Intraday chart for BNP PARIBAS ARBITRAGE/CALL/MODERNA/105/0.1/21.06.24
1 month+177.82%
3 months+368.71%
Date Price Change
24-05-31 3.82 -5.21%
24-05-30 4.03 +5.50%
24-05-29 3.82 -7.51%
24-05-28 4.13 -27.54%
24-05-27 5.7 -3.88%

Real-time Euronext Paris

Last update May 31, 2024 at 12:30 pm

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying MODERNA, INC.
IssuerLogo Issuer BNP Paribas BNP Paribas
G61NB
ISINNLBNPFR1YB50
Date issued 2024-02-13
Strike 105 $
Maturity 2024-06-21 (19 Days)
Parity 10 : 1
Emission price 0.53
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 5.96
Lowest since issue 0.605

Company Profile

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
More about the company

Ratings for Moderna, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: Moderna, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
142.6 USD
Average target price
139.9 USD
Spread / Average Target
-1.83%
Consensus
  1. Stock Market
  2. Warrants
  3. G61NB Warrant